Abstract: A preferred embodiment is provided that utilizes psychedelics that induce the shortest possible hallucinogenic experience, to facilitate the use of fast-acting, short duration anesthetics that creates a state of unconsciousness that eliminates and/or minimizes conscious awareness and/or recall of the hallucinogenic experience. The preferred embodiment facilitates critical brain processes and activities than can potentiate the actions of psychedelics such processing supporting neurogenesis, synaptogenesis while blocking inflammatory cytokine activity particularly in the brain and potentiating the activity of anti-inflammatory cytokines.

Abstract: Systems and methods for the evaluation of clinical treatment efficacy is disclosed. The systems and methods include protocols for selection of appropriate patients/subjects for the evaluation of a specific clinical treatment. The systems and methods are based on objective measures of brain activity. The clinical treatments include pharmacological compounds in development or existing compounds approved by the appropriate regulatory authority (e.g., U.S. Federal Drug Administration), as well as transcranial magnetic or electric stimulation, including non-invasive approaches as well as grid- or depth-based electrode arrays, as well as behavioral therapies.